title: [Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers].
abstract: The 'Stichting Werkgroep Antibioticabeleid' (SWAB; Dutch Working Party on Antibiotics Policy) has developed evidence-based guidelines for the antimicrobial treatment of methicillin-resistant Staphylococcus aureus (MRSA) carriers for the eradication of MRSA. A distinction was made between uncomplicated and complicated carriage depending on the presence or absence of an active MRSA infection, skin lesions, foreign body material, mupirocin resistance and/or extranasal carriage. The indication for treatment is determined by the consequences of carriage for the carrier and his/her environment, the adverse events of treatment, and the likelihood of a successful treatment. The first choice of treatment in uncomplicated carriers is a combination of mupirocin nasal ointment and disinfectant soap for 5 days, along with hygiene advice. If treatment fails, sources in the vicinity of the patient must be sought. Complicated carriers receive a combination of 2 oral antibiotics, in addition to mupirocin nasal ointment and disinfectant soap, for at least 7 days.
authors.affiliation: Erasmus MC-Centrum, afd. Medische Microbiologie en Infectieziekten, Rotterdam.
authors.forename: H F L
authors.initials: HF
authors.lastname: Wertheim
authors.forename: H S M
authors.initials: HS
authors.lastname: Ammerlaan
authors.forename: M J M
authors.initials: MJ
authors.lastname: Bonten
authors.forename: P J
authors.initials: PJ
authors.lastname: van den Broek
authors.forename: A
authors.initials: A
authors.lastname: Troelstra
authors.forename: C M J E
authors.initials: CM
authors.lastname: Vandenbroucke-Grauls
authors.forename: M C
authors.initials: MC
authors.lastname: Vos
authors.forename: A
authors.initials: A
authors.lastname: Voss
authors.forename: J L
authors.initials: JL
authors.lastname: Nouwen
authors.forename: J A J W
authors.initials: JA
authors.lastname: Kluytmans
mesh_terms: D002353:Carrier State; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006920:Hygiene; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D016712:Mupirocin / Q000627:therapeutic use*; D009296:Nasal Cavity / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D016712:Mupirocin